Imvax, Inc.

Imvax, Inc. is a clinical-stage biotechnology company that focuses on developing personalized, whole tumor-derived immunotherapies. The company's combination therapy is distinctive for its ability to capture the complete antigenic signature of a patient's tumor, transforming it into a highly stimulatory 'training program' for the patient's immune system. This comprehensive training aims to stimulate both innate and adaptive immune responses, optimizing long-term anti-tumor effects. Imvax's lead program targets glioblastoma multiforme (GBM), an aggressive form of brain cancer, with additional programs addressing various types of solid tumors. Founded in 2015 and headquartered in the United States, Imvax, Inc. recently secured a $23.00M funding round investment on 06 September 2023. The investors participating in this round have not been disclosed. Imvax's groundbreaking approach to cancer immunotherapy, particularly in the challenging GBM space, showcases its potential for disrupting the biotechnology and pharmaceutical industries.